Becton, Dickinson and Company (NYSE:BDX) 7th Annual Evercore ISI HealthCONx Results Conference December 3, 2024 10:50 AM ET
Company Participants
Richard Byrd – EVP and President of Interventional Business
Chris DelOrefice – Executive Vice President & Chief Financial Officer
Conference Call Participants
Vijay Kumar – Evercore ISI
Vijay Kumar
Thanks, everyone, for joining us this morning. A pleasure to have with us Becton, Dickinson. From the company, we have our CFO, Chris DelOrefice. We also have Rick Byrd, EVP and President of Interventional Business. And I’m Vijay Kumar, Corporate Devices Life Sciences here at Evercore. Chris and Rick, thank you so much for the time this morning.
Richard Byrd
Yes, you bet.
Chris DelOrefice
Our pleasure.
Vijay Kumar
Fantastic. Before we dive into it, I have a list of questions, but if you want to make any opening comments, Chris?
Chris DelOrefice
Yes. Sure. Well, one thanks everyone for joining, and Vijay, thanks as always for having us. Yes. I guess maybe just a quick recap. Right? We just wrapped up fiscal year ‘24, and we set our guide for fiscal year ’25. I think just a few things that I would point out. If you look at fiscal year ’24, strong growth of 5% overall, obviously, the year played out a bit different than we started. We had to adjust for some of these market dynamics, in particular in the tool space.
But if you actually bifurcate kind of the growth profile, we basically had two businesses, BDB, pharm systems that grew low single digits about 1%. The rest of the portfolio inclusive of navigating a low single-digit decline in China was almost 6% growth. Right? So, you see the value and durability of the BD portfolio. And I think when you think of our FY ‘25 guide on growth, similar kind of frame. We still have these market dynamics. We wanted
Credit: Source link
